L 740515
Latest Information Update: 25 Oct 2018
Price :
$50 *
At a glance
- Originator Merck Frosst
- Class Antiasthmatics
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 12 Jun 2001 No-Development-Reported for Asthma in Canada (PO)
- 20 May 1997 New profile
- 20 May 1997 Preclinical development for Asthma in Canada (PO)